转移性癌症的全身化疗和免疫治疗进展

IF 0.4 Q4 SURGERY

Seminars in Colon and Rectal Surgery Pub Date : 2023-09-01 DOI:10.1016/j.scrs.2023.100972

Nikhil Grandhi MD , Bindiya Patel MD , Olivia Aranha MD, PhD

{"title":"转移性癌症的全身化疗和免疫治疗进展","authors":"Nikhil Grandhi MD , Bindiya Patel MD , Olivia Aranha MD, PhD","doi":"10.1016/j.scrs.2023.100972","DOIUrl":null,"url":null,"abstract":"<div><p><span>Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer<span><span> (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, </span>immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and </span></span>mismatch repair deficient tumors.</p></div>","PeriodicalId":55956,"journal":{"name":"Seminars in Colon and Rectal Surgery","volume":"34 3","pages":"Article 100972"},"PeriodicalIF":0.4000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer\",\"authors\":\"Nikhil Grandhi MD , Bindiya Patel MD , Olivia Aranha MD, PhD\",\"doi\":\"10.1016/j.scrs.2023.100972\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer<span><span> (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, </span>immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and </span></span>mismatch repair deficient tumors.</p></div>\",\"PeriodicalId\":55956,\"journal\":{\"name\":\"Seminars in Colon and Rectal Surgery\",\"volume\":\"34 3\",\"pages\":\"Article 100972\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Colon and Rectal Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043148923000325\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Colon and Rectal Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043148923000325","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

摘要

结直肠癌是美国癌症相关死亡的第二大原因。大约25%的患者被诊断为转移性结直肠癌(mCRC)， mCRC的5年生存率低至14%。mCRC的主要治疗是全身治疗，包括化疗、免疫治疗和靶向药物。随着基因组分析技术的进步，我们现在可以为独特的患者群体量身定制治疗方案，提高总体生存率。在这篇综述中，我们讨论了基于肿瘤侧性、KRAS/BRAF野生型与突变型肿瘤的mCRC患者的治疗策略，并回顾了免疫治疗在微卫星不稳定和错配修复缺陷肿瘤中的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Advances in systemic chemotherapy and immunotherapy for metastatic colorectal cancer

Colorectal cancer is the second leading cause of cancer related death in the United States. Approximately 25% of patients are diagnosed with metastatic colorectal cancer (mCRC) and the 5-year survival rate in mCRC is low at 14%. Primary treatment for mCRC is systemic therapy, which includes chemotherapy, immunotherapy, and targeted agents. With advances in genomic profiling, we can now tailor treatment to unique patient populations and improve overall survival. In this review, we discuss treatment strategies for mCRC patients based on tumor sidedness, KRAS/BRAF wild-type versus mutant tumors, and review the benefit of immunotherapy in microsatellite unstable and mismatch repair deficient tumors.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in Colon and Rectal Surgery SURGERY-

CiteScore

0.60

自引率

0.00%

发文量

期刊介绍： Seminars in Colon and Rectal Surgery offers a comprehensive and coordinated review of a single, timely topic related to the diagnosis and treatment of proctologic diseases. Each issue is an organized compendium of practical information that serves as a lasting reference for colorectal surgeons, general surgeons, surgeons in training and their colleagues in medicine with an interest in colorectal disorders.